Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics:
Biogen appears to back away from dealmaking projections: The company’s execs faced questions about dealmaking capacity during the ...
↧